Andrew Civitello, MD
Advanced Heart Failure and Transplant Cardiology · Houston, TXNPI 1104863745
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Abbott at 56.5% of the total. Reporting peaked in 2019 at $9,102 and has fallen 94.2% since, to $531 in 2025.
Across 111 payments — averaging $167.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Medtronic$6K
- Abiomed$591
- Impulse Dynamics (USA) Inc.$181
- Boston Scientific$139
- AstraZeneca$127
- plus $777 from 16 others
Across 70 payments — averaging $3821.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$214K
- Amgen$53K
What the payments were for
- Consulting fees$10,74558%
- Speaking & faculty fees$2,10011%
- Food & beverage$5,70331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $10,480 |
| Medtronic(2 entities) | 15 | $6,253 |
| Abiomed | 8 | $591 |
| Impulse Dynamics (USA) Inc. | 1 | $181 |
| Boston Scientific | 5 | $139 |
| AstraZeneca | 1 | $127 |
| Atricure, Inc. | 1 | $113 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $109 |
| Biomerieux Inc | 2 | $109 |
| Novartis | 4 | $79 |
| Pfizer | 3 | $58 |
| Baxter Healthcare | 1 | $44 |
| Irhythm Technologies, Inc. | 3 | $37 |
| Chiesi USA, Inc. | 2 | $33 |
| Bridgebio Pharma, Inc. | 1 | $33 |
| Analog Devices Inc. | 1 | $33 |
| Amgen | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Mannkind Corporation | 1 | $16 |
| Heartflow, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$7,413
- HeartWare HVAD$6,018
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$850
- HeartMate 3 Left Ventricular Dev$544
- Impella$454
- OPTIMIZER$181
- HeartMate$161
- HeartMate 3 Left Ventricular Assist Device$149
- HeartMate Touch$141
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$134
- FARXIGA$127
- ATRICLIP LAA EXCLUSION SYSTEM$113
- CARDIOMEMS$100
How this compares
$18,548 in reported general payments places this provider in the 55th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $92,021 |
| EntrestoSacubitril/Valsartan | 58 | $58,651 |
| JardianceEmpagliflozin | 23 | $17,254 |
| Tacrolimus | 37 | $7,877 |
| Sirolimus | 13 | $7,184 |
| Valganciclovir Hcl | 17 | $6,041 |
| Mycophenolate Mofetil | 25 | $4,845 |
| Bumetanide | 99 | $3,705 |
| Pravastatin Sodium | 98 | $1,273 |
| Atorvastatin Calcium | 116 | $1,206 |
| Amiodarone Hcl | 16 | $1,076 |
| Carvedilol | 102 | $1,070 |
| Metoprolol Succinate | 79 | $928 |
| Potassium Chloride | 30 | $585 |
| Ezetimibe | 18 | $540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $92,02168 claims |
| NovartisEntresto | $79 | $58,65158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Houston
- Barry TrachtenbergHouston$306K
- Arvind BhimarajHouston$216K
- Ajith NairHouston$80K
- Ashrith GuhaHouston$61K
- Cindy MartinHouston$47K
- Leo SimpsonHouston$30K
- Rayan YousefzaiHouston$8K
- Ju KimHouston$7K
- Sana ShoukatHouston$7K
- Janardhana GorthiHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.